Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Testing Industry Will Benefit As EU Accepts Need To Modernize Screening

Executive Summary

The Council of the EU has adopted recommendations put forward by the European Commission to broaden cancer screening significantly. This is the first time EU cancer screening recommendations have been revised in some 20 years.

You may also be interested in...



EU Taps Power Of AI To Beat Cancer In New Imaging Initiative

The European Commission’s newly-launched Cancer Imaging Initiative will see sophisticated digital technologies based on artificial intelligence used to speed up medical innovations as part of its wider Beating Cancer Plan.

Overdue Revision Of EU Cancer Screening Would Benefit Medtech Industry As Incidence Skyrockets

Council of the EU recommendations on cancer screening have not changed in some 20 years, yet the increase in cancer rates is alarming. Industry associations, COCIR and MedTech Europe have come out in support of the European Commission’s push for a revision.

EU Regulatory Round-Up, January 2023: Cautious Optimism As New MDR Proposal Unveiled

All eyes were on the European Commission in January as it edged closer to adopting new legislation that will see the Medical Device Regulation transition deadlines extended.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel